Angiogenesis Inhibitors as Anti-Cancer Therapy Following Renal Transplantation: A Case Report and Review of the Literature.

Abstract

Solid organ transplant recipients on long-term immunosuppressive medication are at increased risk of developing malignancy, and treatment of advanced cancers with angiogenesis inhibitors in this context has not been widely studied. We present a case of recurrent high-grade serous ovarian carcinoma treated with paclitaxel and bevacizumab in the context of prior renal transplantation where the patient responded well to treatment with controlled toxicities, discussing the potential for increased rates of adverse events and drug interactions in this select population.

• Authors: Lawrence Kasherman, Jeffrey Doi, Katherine Karakasis, Jeffrey Schiff, Abhijat Kitchlu, Stephanie Lheureux, Amit M Oza
• Journal: Current oncology (Toronto, Ont.) (Curr Oncol) Vol. 28 Issue 1 Pg. 661-670 (01 22 2021) ISSN: 1718-7729 [Electronic] Switzerland
• PMID: 33499164 (Publication Type: Case Reports, Review)

Chemical References

• Angiogenesis Inhibitors
• Bevacizumab
• Paclitaxel

Topics

• Angiogenesis Inhibitors (therapeutic use)
• Bevacizumab (therapeutic use)
• Humans
• Kidney Transplantation
• Neoplasms (drug therapy)
• Paclitaxel (therapeutic use)